The trial, sponsored by Allife Medical Science and Technology Co., Ltd., aims to address transfusion-dependent β-thalassemia through innovative gene correction techniques. The market for β-thalassemia treatments is significant, with a growing demand for curative therapies. The competitive landscape includes gene therapies and hematopoietic stem cell transplantation options. Successful outcomes could position Allife as a leader in the gene therapy space, potentially attracting partnerships or acquisition interest. However, the trial's single-center, open-label design may limit the robustness of data compared to multi-center, randomized trials, which could impact investor confidence and market perception.